Cargando…
Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort
Deflazacort (Emflaza) was approved in the United States in 2017 for the treatment of the Duchenne muscular dystrophy in patients aged 2 years and older. Several deflazacort metabolites were isolated and identified from rats, dogs, monkeys, and humans. Among them, 1ß,2ß‐epoxy‐3ß‐hydroxy‐21‐desacetyl...
Autores principales: | Kong, Ronald, Ma, Jiyuan, Beers, Brian, Kaushik, Diksha, Lin, E, Goodwin, Elizabeth, Colacino, Joseph, Bibbiani, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580709/ https://www.ncbi.nlm.nih.gov/pubmed/33090712 http://dx.doi.org/10.1002/prp2.677 |
Ejemplares similares
-
In vitro cytochrome P450‐ and transporter‐mediated drug interaction potential of 6β‐hydroxy‐21‐desacetyl deflazacort—A major human metabolite of deflazacort
por: Ma, Jiyuan, et al.
Publicado: (2021) -
Deflazacort-induced Acneiform Eruptions
por: Bashir, Mohammed Shakeel Mohammed, et al.
Publicado: (2017) -
Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids
por: Parente, Luca
Publicado: (2017) -
Sphingolipids and Epoxidized Lipid Metabolites in the Control of Gut Immunosurveillance and Allergy
por: Kunisawa, Jun, et al.
Publicado: (2016) -
DEFLAZACORT VERSUS OTHER GLUCOCORTICOIDS: A COMPARISON
por: Nayak, Surajit, et al.
Publicado: (2008)